The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide.
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Inclusion Criteria:
Exclusion Criteria:
Phase 1
Enrollment: 12 patients (estimated)
View MoreJune 11, 2021
Safety and tolerability data:
Of the six patients dosed at the first two dose levels (30×106 and 100×106 cells per infusion):
Clinical activity:
Of the five evaluable patients at the first two dose levels (30×106 and 100×106 cells per infusion):
Cell kinetics:
Next steps:
Read the latest news and updates on this trial.
View all clinical trial locations sorted by state.
New York, NY
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message